DRG Market Research

Follow DRG experts for market-related insights, blogs, and other content focused on cardiovascular, metabolic, renal, and hematology disorders.

[DRG Market Research @CMRH_TeamDRG]

Starting August 23, this Twitter account is no longer be active. Please follow @ClarivateHealth to continue receiving important #DRG updates: https://t.co/RzyA3VjHuR

[DRG Market Research @CMRH_TeamDRG]

#acutecoronarysyndrome https://t.co/0tVrbwnI3U

[Clarivate Epidemiology @DRG_Epi]

#DRG estimates prevalence of #acutecoronarysyndrome highest in Middle East and Africa at 5 per 1,000 #heartattack acute #coronarysyndrome @DRGinsights

[DRG Market Research @CMRH_TeamDRG]

FDA approves expanded use of Auryxia @keryxbiopharma https://t.co/k1Vb9sbw73

[Jihan Khan @jkhanDRG]

Ferric Citrate: Killing Two Birds with One Stone in CKD? | Drug Watch | DRG https://t.co/K30zgbk0U3

[DRG Market Research @CMRH_TeamDRG]

#type2diabetes https://t.co/JWBoVpy30P

[Jihan Khan @jkhanDRG]

ITCA-650’s Opportunity in the Type 2 Diabetes Market | Drug Watch | DRG https://t.co/pK3KETZ0Py

[DRG Market Research @CMRH_TeamDRG]

Understanding renal anemia among patients with #kidney disease #kidneyweek https://t.co/tGBmTCtNZg

[Jihan Khan @jkhanDRG]

DRG Expects the Renal Anemia Market to Reach More than $6 Billion in 2026 Driven By the Emergence of the Novel HIF-P…https://t.co/bwfGDEvmBV

[DRG Market Research @CMRH_TeamDRG]

Obesity Week 2016 at The Big Easy – Here we go! | DRG Blog | DRG https://t.co/YQ4aMGHvdZ

[DRG Market Research @CMRH_TeamDRG]

#OW2016 https://t.co/oPE4j1YLqx

[DRG Market Research @CMRH_TeamDRG]

Follow expert @TBlackstock_DRG for more updates during obesity week! #OW2016 https://t.co/RZeT9zSGf9

[Clarivate Epidemiology @DRG_Epi]

#DRG reports #obesity cases in US, Japan, EU5 will increase 14% by 2036 https://t.co/56DigLiwpf

[DRG Market Research @CMRH_TeamDRG]

#glomerulonephritis https://t.co/9O8BfKDSTF

[Jihan Khan @jkhanDRG]

Study Reveals Nephrologists Unaware Of Glomerulonephritis Therapies In Development | DRG Blog | DRG https://t.co/Yty6yeoDHn

[DRG Market Research @CMRH_TeamDRG]

Register now! https://t.co/obSX86r6FJ

[Jihan Khan @jkhanDRG]

Insights into the Chronic Kidney Disease Market - Anticipated Impact of Emerging Therapies | Events | DRG https://t.co/UzKnxeoXLP

[DRG Market Research @CMRH_TeamDRG]

learn more about #heartfailure from expert @drudnicka_DRG https://t.co/Mv82kHTxkr

[DRG Market Research @CMRH_TeamDRG]

DRG's renal expert @jkhanDRG weighs in on growing strength of @ViforPharma kidney portfolio https://t.co/RaizgAo52t

[Jihan Khan @jkhanDRG]

Is Vifor Fresenius Medical Care Renal Pharma The Next Leading Care Provider In Renal Disorders? – DRG Blog – DRG https://t.co/P01i337ywJ

[DRG Market Research @CMRH_TeamDRG]

EU docs rely on reps. Here’s three ways pharma can better support them – Digital Innovation – DRG https://t.co/nYaVR9aNGG

[DRG Market Research @CMRH_TeamDRG]

#Roxadustat enrolls first patient into phase III in Japan- check out DRG insights from @jkhanDRG https://t.co/0gR04wAfMv

[Jihan Khan @jkhanDRG]

Will HIF-PH Inhibitors Be The Future of Renal Anemia Treatment? Nephrologists and Payers Weigh In – DRG Blog – DRG https://t.co/HcBCcdmMZw

[DRG Market Research @CMRH_TeamDRG]

#Mircera sales growing quickly- expert insights from @jkhanDRG https://t.co/kefKULB17y

[Jihan Khan @jkhanDRG]

Epogen vs. Mircera: The Battle Heats Up! – DRG Blog – DRG https://t.co/nO51EWuK3h

[DRG Market Research @CMRH_TeamDRG]

Insights into #phosphate binder prescribing #Velphoro #Renvela https://t.co/vK5d1dXXw1

[Jihan Khan @jkhanDRG]

Renvela to Velphoro: To Switch or Not to Switch, That is the Question – DRG Blog – DRG https://t.co/csGcpZrhg4